DiaMedica Therapeutics Inc expected to post a loss of 18  cents a share - Earnings Preview

DiaMedica Therapeutics

09/08/2022 03:04

* DiaMedica Therapeutics Inc  DMAC.OQ   DMAC.O  is expected
to show no change in quarterly revenue when it reports 
results on August 10. 
    * ​Refinitiv's mean analyst estimate for DiaMedica
Therapeutics
Inc is for a loss of 18 cents per share. For the same quarter
last year, the company reported a loss of 17 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for DiaMedica
Therapeutics Inc is $12​, above​ its last closing price
of $1.78. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.16       -0.21      -0.13     Beat    39.1
 Dec. 31 2022              -0.18      -0.10     Beat    43.2
 Sep. 30 2021  -0.21       -0.23      -0.18     Beat    21.1​
 Jun. 30 2021  -0.20       -0.21      -0.17     Beat    19.7
 ​​Mar.        -0.21       -0.21      -0.19     Beat    10.9
 31 2021                                                
 Dec. 31 2020  -0.18       -0.17      -0.23     Missed  -36.9​
 Sep. 30 2020  -0.15       -0.15      -0.19     Missed  -29.5
 Jun. 30 2020  -0.16       -0.15      -0.17     Missed  -10.9
 This summary was machine generated August 9 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated